Neutrophil gelatinase associated lipocalin (NGAL) is elevated in type 2 diabetics with carotid artery stenosis and reduced under metformin treatment

• Published in: Cardiovascular diabetology Vol. 16; no. 1; p. 98
• Main Authors: Eilenberg, W, Stojkovic, S, Piechota-Polanczyk, A, Kaider, A, Kozakowski, N, Weninger, W J, Nanobachvili, J, Wojta, J, Huk, I, Demyanets, S, Neumayer, C
• Format: Journal Article
• Language: English
• Published: England BioMed Central 08.08.2017; BMC
• Subjects: Aged; Antidiabetics; Atherosclerosis; Bioindicators; Biomarkers - blood; C-reactive protein; Cardiology; Cardiovascular disease; Carotid arteries; Carotid Arteries - metabolism; Carotid artery; Carotid Artery Diseases - metabolism; Carotid artery stenosis; Carotid Stenosis - complications; Carotid Stenosis - metabolism; Coronary vessels; Cytokines; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - metabolism; Embolization; Enzyme-linked immunosorbent assay; Female; Fibrinogen; Gelatinase; Gelatinase B; Gene expression; Health risk assessment; Hemorrhage; Humans; Hypertension; Inflammation; Insulin resistance; Lesions; Leukocytes (neutrophilic); Lipocalin; Lipocalin-2 - metabolism; Male; Matrix metalloproteinase; Metalloproteinase; Metformin; Metformin - therapeutic use; Middle Aged; Neutrophils; NGAL; Original Investigation; Phosphorylation; Plaques; Proto-Oncogene Proteins - blood; Regression analysis; Stenosis; Surgeons; Surgery; Thrombosis; Tumor necrosis factor-TNF; Type II diabetes; NGAL; Lipocalin; Atherosclerosis; Type II diabetes; Inflammation; Metformin; Carotid artery stenosis
• ISSN: 1475-2840; 1475-2840
• DOI: 10.1186/s12933-017-0579-6

Neutrophil gelatinase-associated lipocalin (NGAL), an acute phase protein released by neutrophils, has been described as biomarker of inflammatory states. Type 2 diabetes mellitus (T2DM) is characterized by increased inflammation and an elevated risk for embolization of carotid artery stenosis (CAS). We aimed to explore the role of NGAL systemically and in plaques of diabetics undergoing carotid endarterectomy. Moreover, the potential anti-inflammatory effect of metformin on NGAL was addressed in diabetics. Serum NGAL and matrix metalloproteinase (MMP)-9/NGAL levels were measured in 136 patients (67 with T2DM vs. 69 non-diabetics) by specific ELISA. Endarterectomy samples were graded histologically according to the American Heart Association´s classification. NGAL mRNA expression was detected using RealTime-PCR in carotid endarterectomy specimens. Serum NGAL [median 107.4 ng/ml (quartiles: 75.2-145.0) vs. 64.4 (50.4 -81.3), p < 0.0001] and MMP-9/NGAL [41.5 ng/ml (20.8-63.9) vs. 27.6 (16.0-42.4), p = 0.017] were significantly elevated in diabetics compared to non-diabetics, as were leukocytes, neutrophils, C-reactive protein and fibrinogen (all p < 0.05). In patients with symptomatic and asymptomatic CAS diabetics had higher NGAL levels compared to non-diabetics [128.8 ng/ml (100.8-195.6) vs. 64.8 (48.9-82.2] and [101.6 ng/ml (70.1-125.3) vs. 63.8 (51.0-81.3), respectively, both p < 0.0001]. Presence of T2DM and type VI plaques (with surface defect, hemorrhage or thrombus) had a profound impact on NGAL levels (both p < 0.01) in multiple linear regression analysis. NGAL mRNA was detectable in 95% of analyzed carotid artery lesions of diabetics compared to 5% of non-diabetics (p < 0.0001). Accordingly, cerebral embolization was more frequent in diabetics (52.2% vs. 29%, p = 0.006). Metformin treatment was associated with decreased NGAL [60.7 ng/ml (51.9-69.2) vs. 121.7 (103.7-169.9), p < 0.0001] and MMP-9/NGAL [20.8 ng/ml (12.1-26.5) vs. 53.7 (27.4-73.4), p = 0.007] in diabetics and reduced leukocyte infiltration in carotid lesions of diabetics. Higher NGAL levels in serum and plaques are associated with T2DM in patients with CAS. Metformin significantly reduced the inflammatory burden including NGAL in diabetics. Early treatment of these patients may be recommended, as elevated NGAL levels were linked with vulnerable plaques prone for embolization.